Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

Posted: October 13, 2022 at 2:26 am

PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia.

See more here:
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

Related Posts